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Summary Photofrin II (dihaematoporphyrin ether/ester, DHE) was labelled with indium-i 11 and its biodis-
tribution in tumour bearing mice compared with that of "'In chloride. The uptake and clearance of "'In
labelled DHE differed markedly from that of indium-l 1 chloride in that the former was not taken up by the
tissues as much as the latter. Scintillation scanning with a gamma-camera showed marked uptake of both "'In
agents at the site of the tumour, but a much lower tissue background (excluding the abdominal organs) for the
mice given "'In DHE. Tumour:muscle ratios of dissected tissues were 2-3 times higher in "'In DHE treated
animals as compared to the uptake of "'In chloride. There was a distinct difference in the pattern of
distribution of the two "'In preparations in the tissues. The major accumulation of "'In chloride was in the
kidneys, whereas the highest uptake of "'In DHE was in the liver, the organ in which unlabelled porphyrins
accumulate. Extraction and testing of materials from tumours of "'In DHE treated animals indicated that
most of the tumour extractable "'In had remained associated with the porphyrin in vivo up to 4 days after
injection.
Haematoporphyrin derivative (HPD) is a mixture of sub-
stances, some of which are known to localise in tumours and
to fluoresce upon exposure to light at the appropriate wave-
lengths. The consequent release of a singlet oxygen leads to
photosensitivity and cytotoxicity, the basis for photodynamic
therapy. It is characteristic of many photosensitisers such as
porphyrin derivatives, chlorins and phthalocyanins to exhibit
preferential accumulation in tumour compared to normal
tissue (with the exception of the liver, spleen and kidneys in
which these compounds accumulate at high concentrations).
Dougherty (1987) and Kessel (1986a,b) have shown that
dihaematoporphyrin esters or ethers (DUE) and some oli-
gomers of DHE play major roles in the tumour uptake of
HPD. The use of DHE for photodynamic therapy clearly
necessitates selective uptake and retention of this agent by
the tumour. Hence, a radiolabelled DHE which could be
used for in vivo scanning and quantitative measurement of
uptake would be of potential value in this form of therapy.
The present work was undertaken to study the in vivo
distribution of DHE radiolabelled with indium-111 to deter-
mine if this gamma-emitting metalloporphyrin could be used
for gamma camera scanning and quantitative measurement
of uptake in tumour tissue in vivo. For this purpose DHE
(QLT, Phototherapeutics, Inc., Vancouver, BC, Canada) was
radiolabelled with indium-111 according to a previously des-
cribed procedure (Lavallee & Fawwaz, 1986) and its uptake
and distribution were measured in tumour bearing mice by
scintiscanning and by direct counting of dissected tissues.
Photofrin II is a preparation of haematoporphyrin derivative
enriched for di- and oligoporphyrin ethers (or esters) and is
denoted as DHE in this report.
Materials and methods
Labelling ofPhotofrin II with indium-l1l
Dihaematoporphyrin ether (DHE, Photofrin II) was obtained
from Quadralogic Technologies Inc. at a concentration of
2.5mgml1' in normal saline. Carrier-free indium-111
chloride in 0.05M HCI was obtained from Merck Frosst
Canada Inc. (prepared by Atomic Energy of Canada Ltd) at
a specific activity of 74-333 MBq (2-9 mCi) ml-I and con-
centration of 9.3-42.0 ng ml-'.
The binding of indium-1Il to DHE was carried out by an
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adaptation of the method of Lavallee and Fawwaz (1986).
The DHE was lyophilised or crystallised at pH 2.5 before
being dissolved in water-free glacial acetic acid buffered with
40-50 mg per 100 ml of sodium acetate. Some of the experi-
ments were carried out with a DHE solution in acetic acid-
sodium acetate buffer kindly provided by Dr Lavallee. After
the incubation of the DHE solution with heat-dried "'In
chloride for 75 min at 65°C, the acetic acid was evaporated
off in a nitrogen stream and the material was redissolved in
an aqueous solution of 150 mM NaCl mixed 1:1 with 1 M
Na2CO3.
In order to separate the unbound "'In, the radiolabelled
DHE was passed through a silica gel column. 'Seppak' Silica
cartridges (Waters Associates, part no. 51900, Milford, MA,
USA) were found suitable for this, following a brief passage
of absolute alcohol through the column. The solvent used to
passage the radiolabelled material was a mixture of ethanol,
water, ethylacetate, ammonium hydroxide (4:2:2:1), the same
as that used for silica gel TLC ('Baker-flex' (flexible sheets
for thin layer chromatography), silica gel, code IBF-F, J.T.
Baker Chemical Co., Phillipsburg, NJ, USA). With this sol-
vent mixture, free unbound "'In was retained by the column.
In the final preparation, atiout 94-97% of the "'In was
bound to DHE which passed freely through the column. The
solution which passed through the silica gel column was
evaporated and the brown residue redissolved in the aqueous
solution of 150 mM NaCl: 1 M Na2CO3. This solution was
injected intravenously without adverse effect. The specific
activity of the final injected solution was 2-8 ILCi;Lg-'. The
total administered dose of 0.74-1.85 MBq (20-50PCi) con-
tained 87-218 pg of "'In and an estimated 2.5-25 ltg of "'In
DHE was given per mouse.
Experimental model
DBA/2J mice (Jackson Laboratories, Bar Harbor, MA,
USA) weighing about 20g were injected in the right thigh
with MI rhabdomyosarcoma cells (20,000 cells per mouse).
The cell line was originally induced by methylcholanthrene
and was maintained by serial in vivo passage. After about 2
weeks, the tumours were approximately 1 cm in diameter and
usually were not haemorrhagic or necrotic on direct exam-
ination. However, tumours which were larger than 1.5cm
diameter often did appear necrotic and haemorrhagic and did
not label well with the "'In DHE.
Biodistribution studies
About 1.85 MBq (50 GCi) bound to 7.5-10jig DHE, and
containing about 100 pg of "'In, were injected through the
Br. J. Cancer (1990), 62, 885-890 '." Macmillan Press Ltd., 1990886 M.R. QUASTEL et al.
tail vein of each mouse. Other animals were given the same
dose of "'In chloride in saline for comparison. In some
experiments, gamma-camera images were obtained at varying
intervals after administration of the agent. In these studies,
between 15,000 and 30,000 counts were accumulated with the
barbiturate treated sleeping mouse lying prone on the surface
of the camera. Analyses were carried out by region-of-
interest (ROI) measurements over the tumour, contralateral
thigh, upper abdomen, head and neck area, and over the
whole body. In this way, the "'In content of the area over-
lying an organ or tumour could be measured by external
scanning and expressed in terms of the whole body content.
In other experiments, the "'In content of various organs was
assessed as follows. The animals were killed by cervical dis-
location during ether anaesthesia. The inferior vena cava was
nicked to allow much of the circulating blood to drain off.
Samples of liver, spleen, kidney, tumour, thigh muscle, duo-
denum, blood, brain, skin, lung and thymus were obtained
and wet-weighed before gamma counting in a well type scin-
tillation counter. The results were expressed in terms of the
percentage of the injected dose per gram (wet weight) of
tissue. The tumour when opened sometimes contained bloody
fluid. This was blotted off and the pinkish glistening tumour
tissue was collected for analysis.
This distribution of radioindium administered bound to
DHE or as the chloride was measured 18 h after injection,
and the results were compared to those of Gomer and
Dougherty (1979), who used 14C and 3H labelled HPD, and
of Bellnier et al. (1988) who used '4C DHE. Their values
were expressed in terms ofpg g 1, and are plotted as such in
the ordinate of Figure 4b, for comparison with our results.
Figure 4a includes results obtained by Saha and Farrer
(1975) for the uptake of "'In chloride.
Extraction ofDHEfrom tissues
Since the chloroform-methanol extraction technique of
Kessel (1986a,b) was unsuitable due to the low solubility of
"'In DHE in the solvent used, a technique was adapted from
that of Dougherty and Mang (1987); this was found to be
more satisfactory since indium-i 11 DHE could be clearly
separated in the ethylacetate phase (Table I). However, the
final step of the latter procedure using HCI could not be
applied to the metallated porphyrin prepared in this study.
The tissues were pressed through a wire mesh into distilled
water and frozen overnight. After thawing, the preparation
was placed in 5 ml of 150 mm acetic acid and further dis-
rupted by ultrasound. Fifty millilitres of 3:1 ethylace-
tate:glacial acetic acid was added and the solution stored at
4°C for an hour. This was followed by filtration through
glass wool. The mixture was extracted with 25 ml saturated
sodium acetate, followed by extraction twice with ethyl-
acetate. About 50-80% of the total tumour radioactivity
could be extracted in this way, the remainder staying with the
insoluble material and not removed by further ethylacetate
extractions. "'In chloride showed a similar degree of tissue
retention, but was not extracted with ethylacetate. Recovery
rates achieved here are comparable to those obtained by
ourselves and other investigators using either 14C labelled
porphyrins or unlabelled photosensitisers quantified spectro-
photometrically.
Table I Solubility of 1"InCl3 and "'In-DHE in ethylacetate and in
saturated sodium acetate
Results
Imaging in vivo with "'In-DHE and "'In-chloride
As shown in Figure 1, pronounced radiolabelling of the
tumour area was clearly observed by scintiscanning 1 h and
16 h following the injection of each agent. However, "l'In
DHE was found at far lower concentrations in the peripheral
tissues (e.g. muscle), as is apparent from the markedly lower
uptakes in the contralateral limb and head area, as compared
to the higher retention of radioisotope in the tissues of mice
given "'In chloride.
The whole body content of "'In for six mice treated with
radiolabelled DHE or with the chloride is shown in Figure 2,
which indicates that for DHE, about 2/3 of the injected
radioindium was lost from the body after 18 h (after correct-
ing for radioactive decay). In four repeated experiments
(6-10 mice per experiment), 1/2 to 2/3 of the injected dose of
radiolabelled DHE was lost after the first day, with a much
slower release after this period. In contrast, "'In admini-
stered as the chloride showed much more pronouced whole
body and tissue retention.
By repeated imaging of each animal followed by region-of-
interest (ROI) measurements of the digital images, it was
found that the prominent uptakes of "'In chloride or of "'In
DHE into the tumour areas were proportional, respectively,
to the amount of "'In measured over the contralateral thigh
area (Figure 3). Although the tumours seemed to take up
relatively less of the radiolabelled DHE, compared to "'In
given as the chloride, the tumour:muscle ratios found by ROI
analyses of imaging data were very similar for both "'In
preparations. These in vivo results are in contrast to the tissue
dissection analyses, in which tumour:muscle ratios were signi-
ficantly elevated for "'In DHE (see below).
The question therefore arose whether the radioactivity
detected by scintillation scanning over the contralateral thigh
represented "'In in the circulating blood or immobilised in
the tissues. As shown in Figure 3, there was little or no fall in
the "'In content of peripheral tissue or tumour over 18 h
after the first ROI measurement at 2 h, in spite of the known
fact that blood concentrations for both DHE and "'In
chloride fall markedly during the first day (Bellnier et al.,
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Ethylacetate 2%a 92%
Aqueous phase (saturated sodium 98% 8%
acetate)
a% uptake refers to fraction of added "'In extracted into the
ethylacetate or aqueous phases, according to the method ofDougherty
and Mang (1987).
Figure 1 Gamma scintillation images of six mice that had been
injected with "InCi3 (1,2,3) or "'In-DHE (4,5,6). Each of the
tumour-bearing mice received approximately 501Ci of either
agent through the tail vein. a, I h after i.v. injection. b, 16 h after
i.v. injection.
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Figure 2 In vivo distribution of "'In in tumour-bearing mice
over a period of 4 days, following the i.v. injection of 50 fsCi of
either "'.mICI3 or "'In-DHE. Values were obtained by ROT
analysis of gamma scintillation images, the first of which was
obtained 2 h after administration. The term 'liver area' refers to
an ROT drawn around the heavy concentration in the upper
abdomen. The term 'remaining' refers to total body radioactivity
minus abdominal and tumour radioactive content.
Tumor Tissue
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Figure 3 In vivo measurement of "'.In content of tumour com-
pared to contralateral thigh and head area, for six mice injected
i.v. with "'.mIC13 or "'In-DHE 2, 18 and 97 h previously. Same
animals as in Figure 4.
1988; Saha & Farrer, 1975). In measurements using six mice,
whole blood levels of radiolabelled DHE decreased from
0.45 ± 0.05 to 0.09 ± 0.01% of injected dose per ml during
4-26 h after injection. Hence, radioactivity measured over
the contralateral thigh or head area by ROT analysis of in
vivo images does not represent blood "'In content.
The opposite seems to be true for the liver. There was a
marked decrease of activity over the liver area in parallel to
the fall of whole body content of radiolabelled DHE during
the first 18 h (Figure 2). However, no such decrease was
observed by the direct counting of perfused and dissected
liver samples, which were largely cleared of blood, over
4-26 h after injection. The fall in liver "'in content measured
in vivo by ROT analysis may therefore be due to a decrease in
the blood level of "'In and/or rapid passage to the gut via
the biliary system.
Tissue analyses
In three separate experiments, the tissue distribution of "'In
was measured from the content of radioindium per gram wet
weight shortly after killing the mice under ether anaesthesia.
The results of one experiment using six tumour bearing mice
compares the tissue content after 18 h of radioindium given
either as the chloride or bound to DHE are shown in Figure
4a and b. The former appeared at highest concentration in
the kidneys (Figure 4a) in agreement with the work of Saha
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Figure 4 Tissue distribution of "'In 18 h following the i.v. injec-
tion of 5O.tLCi of "'.mICi3 (a) or "'.In-DHE (b). Presence of "'In
in dissected tissues is denoted as the fraction of the injected dose
per gram wet weight of tissue. Ordinate on the right side of lower
graph indicates uptake of 3H-HPD (0), `4C-HPD (0) of '`C-
DHE (X) as previously reported (Gomer & Dougherty, 1979;
Bellnier et al., 1988). Filled squares represent the 24 h tissue
distribution of "'.mICI3 as found by Saha and Farrer (1975).
These results were obtained after injecting the agents i.v. into six
tumour-bearing mice.
and Farrer (1975). In contrast, radiolabelled DHE was taken
up mainly by the liver. The organ distribution of DHE was
very similar to that reported by Gomer and Dougherty
(1979) with 3H and '4C-HPD and by Bellnier et a!. (1988)
using '4C-DHE. Data from the latter reports are added to
Figure 4b for comparison with the present results using "'In
labelled DHE. In another experiment done with animals
bearing very large tumours (which were largely necrotic and
haemorrhagic), a similar organ distribution was obtained, but
much less radiolabelled DHE appeared to enter or be retain-
ed by the tumours.
Table II presents "'In content and tissue:muscle ratios 18 h
after injection of "'In labelled DHE or chloride. Tumour:
thigh muscle ratios were highest for DHE (P<0.005). These
results, obtained from dissected tissues of 13 tumour bearing
mice in three separate experiments (one of which is shown in
Table II Tissue distribution of "'.InCl3 and "'In-DHE
% uptake/gram wet weight Tissue:muscle ratio
"'1InC!3 "'In-DHE
Tissue (6 mice) (7 mice) "'1InC!3 "'In-DHE
Tumour 5.2 ±0.7 5.8 ±0.4 5.7±0.7 15.3± 1.9
Liver 5.7 ±1.1 19.4 ±1.4 6.1±0.8 50.9±5.7
Kidney 15.8 ±1.6 6.2 ±0.8 17.4± 1.8 15.2± 1.3
Spleen 5.8 ±1.6 7.5 ±1.6 6.4±0.6 18.5±3.1
Lung 4.2 ±1.0 5.0 ±0.4 4.3±0.8 13.3±1.8
Skinofear 2.2 ±0.0 1.9 ±0.6 2.4±0.1 3.2±1.8
Bone+ 3.0 ±0.3 1.8 ±0.3 3.2±0.2 4.5±0.5
marrow
Muscle (opp. 0.90±0.05 0.40±0.05
thigh)
Values are mean±s.d. Animals were killed 18 h after administration
of the "'In labelled agents.
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Figure 4), differ from the in vivo ROI analyses in which the
ratio of "'In measured by imaging over the tumour area to
that over the contralateral thigh was the same for either
administered agent (Figure 3).
The difference between the results of in vivo ROI imaging
and those obtained by direct counting of dissected tumour
and muscle could be due to collection of "'In transferrin in
the exudate and edematous tissue surrounding the tumour,
since this would be detected by in vivo scintiscanning but not
by direct counting of dissected tumour. In Table III, the
fraction of injected "'In chloride detected in the tumour area
by both methods is compared to the uptake of radiolabelled
DHE. It is seen that for "'In DHE, tumour uptake as
measured by in vivo scanning compared well with the count-
ing ofdissected tumour tissue. In contrast, a large fraction of
the injected "'In chloride (about 73%) detected by in vivo
imaging over the tumour area was not found in the dissected
tumour, and therefore must have localised in adjoining tis-
sues. In support of this hypothesis preliminary analysis of
fluid exudate in tumours showed "'In chloride to concentrate
after 18 h to three times that present in the blood.
Estimation ofdissociation of"'In-DHE in vivo
About 80% of the radioactivity extracted from tumours of
mice given "'In DHE a day earlier moved in TLC at
Rft0.8, whereas the remaining radioactivity did not migrate
in the solvent used. In contrast, all the tumour radioactivity
extracted a day after given "'In chloride remained at the
origin of the TLC strip. This indicated that "'In given as the
chloride did not bind or remain bound to any tissue constit-
uent that moved in the silica gel TLC with the solvent
solution used.
A further estimate of the degree of dissociation was made,
based on the high solubility of "'In DHE in ethylacetate, its
low solubility in the aqueous phase, and the opposite
solubility of "'In chloride (Table I). In three separate experi-
ments after "'In DHE injection, 81.8±2.5% (two mice),
74.0 ± 1.5% (three mice) and 87.9±4.6% (five mice) of the
tumour-extractable radioindium appeared in the ethyl acetate
phase one day after administration. After a 4-day interval,
74.0± 1.5% (three mice) was present in the ethylacetate
phase. When "'In was given as the chloride, all tumour or
liver "'In passed into the aqueous phase, and the amount
extracted into ethylacetate was insignificant.
Extraction from the tissues was never complete. About 1/2
to 3/4 of tumour "'In could be extracted by the technique
described from tumours ofmice that had received "'In DHE.
Less was extractable from the liver. For example, in one
experiment with five mice, 33.6 ± 4.3% of tumour "'In was
not extractable, and 74.2 ± 2.4% was not extracted from the
liver.
or the tumour uptake of the radiolabelled DHE. To examine
this question, "'In DHE and unlabelled DHE were injected
simultaneously into tumour bearing mice and the tissue dis-
tribution was compared with another group of mice given
only "'In DHE. The amount of radiolabelled DHE given to
each animal was 4fg, and the total amount of additional
unlabelled DHE was 125tLg per mouse.
The results of the experiment are shown graphically in
Figure 5. Four animals received "'In DHE alone, and
another four were given both the radiolabelled and 'cold'
DHE simultaneously. The animals were killed after 18 h, and
the radioindium content of the tumour and tissues was
measured by gamma counting of the dissected tissue samples.
When the unlabelled DHE was also given, the mean uptake
of "'In DHE by the liver was lower by 26% (P<0.01) and
the tumour content was found to be 42% higher (P<0.025),
than the uptake of radiolabelled DHE given alone.
Discussion
The use of porphyrins in cancer diagnosis and therapy is
based both on their phototoxic properties (Raab, 1900;
Haussman, 1911) and on the localisation of fluorescent por-
phyrins in neoplastic tissues (Policard, 1924; Auler & Banzer,
1942; Figge et al., 1948). A derivative of haematoporphyrin
(HPD) has been widely used for tumour detection and
photodynamic therapy (PDT) over the past two decades
(Lipson et al., 1961; Diamond et al., 1972). However, it has
been difficult to identify the specific tumour localising and
phototoxic principles of HPD, which is known to be a com-
plex mixture of different prophyrins. Putative candidates are
the dihaematoporphyrin ethers or esters (Dougherty et al.,
1984; Kessel & Cheng, 1985). A purification product of
HPD, known commercially as Photofrin II or DHE, contains
less than 20% of inactive monomers and more than 80% of
the active porphyrin dimers and oligomers. Use of the term
DHE in this report refers to the latter product.
Photodynamic therapy with DHE requires its presence in
the tumour. Although fluorescence of tumours has been a
hallmark of HPD uptake, it does not necessarily follow that
the phototoxic compound taken up into the tumour is iden-
tical to the fluorescent agent. Therefore, a direct method of
assessing the amount of DHE taken up into the tumour in
vivo would be of value to determine the probable benefit of
PDT, since if the tumour did not taken up the agent, PDT
would be ineffective. A radiolabelled DHE that would
localise at the tumour site and could be imaged by the
gamma-camera would thus be useful for the quantitative
estimation of DHE uptake.
A number of workers have investigated the possible use of
Effect ofunlabelled DHE on the tissue uptake of"'In DHE
If "'In DHE were to be used as a 'tracer' for DHE in vivo, it
would be important to know the degree to which unlabelled
DHE in molecular excess might affect the tissue distribution
Table III % tumour uptake ofradioindium based on in vivo imaging
compared with direct counting ofdissected tumour
% uptake per gram of
In vivo ROI over tumour dissected tumour
Agent area (no. ofmice)a (no. ofmice)
"mInCI3 21.3±4.3% (3) 5.8±0.4% (6)
"'In-DHE 5.3±1.9% (3) 5.2±0.7% (7)
Values are means±s.d. aRegion ofinterest (ROI) calculations were
made 16 h after injection ofthe radiolabelled agent using six mice and
werecalculated from thetotal countsmeasured overthetumourdivided
by the total body count obtained from the scintiscan. bThe values for
dissectedtumour(seealsoTableII)wereexpressed as % ofinjecteddose
per wetweight. Since the total wet mass ofthe tumour was ofthe order
of 1 g the estimated % total tumour uptake is roughly the same
numerically as in this column for comparison with the ROI data.
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Figure 5 Effect of excess non-labelled DHE on tissue uptake of
"'In-DHE 18 h after i.v. injection via the tail vein of eight
tumour-bearing mice. Histogram with light bars represents the
tissue uptake of "'In-DHE. The dark bars present results
obtained after giving "'In-DHE supplemented by excess DHE
(molar ratio increased by a factor of 16) at the phototherapeutic
level of 1.5mg DHE kg-'."'IN DIHAEMATOPORPHYRIN ETHER 889
radiolabelled porphyrins and metalloporphyrins for tumour
detection in vivo (Figge et al., 1948; Manganiello & Figge,
1951; Bases et al., 1958; Winkelman et al., 1962), but with
varying degrees of success. A major problem with the use of
these agents has been their high degree of accumulation in
the liver, spleen and kidneys (Hambright et al., 1975; Dene-
chaud et al., 1981; Zanelli & Kaelin, 1981). Attempts to
image tumours with "'In labelled porphyrins have been
limited (Vaum et al., 1982; Foster et al., 1985). In summary
of past studies, encouraging tumour localisations of radio-
labelled porphyrins have been demonstrated in animal
models, but the limited human studies have not shown
tumour localisation, possibly due to dissociation of the
radiolabel from the porphyrin in vivo or to a metallation-
induced loss of the tumour localising property of the por-
phyrin preparation.
In the present experiments using DBA/2J mice bearing
transplanted rhabdomyosarcomas, marked tumour uptake of
"'In DHE was observed. The DHE was radiolabelled with
"'In by a method adapted from that of Lavallee and Fawwaz
(1986) in which heating of DHE was kept not greater than
65°C. The following four experimental findings suggest that
"'In DHE has biological properties similar to those of DHE:
(a) The tissue and tumour distribution "'In DHE in vivo, as
measured from the radioindium content of perfused and
dissected tissues, was very similar to that found for '4C and
3H-HPD (Gomer & Dougherty, 1979) and '4C-DHE (Bellnier
et al., 1988) as shown in Figure 4. (b) About 80% of the
tumour-extractable "'In that had been administered bound
to DHE remained after 1 day or more associated with the
porphyrin in vivo, as estimated by its extraction with ethyl-
acetate, whereas "'In given as the chloride was not extracted
into the ethylacetate phase. (c) Tissue distribution studies of
"'In DHE were carried out using "'In chloride as control to
rule out the possibility that "'In may dissociate in vivo from
DHE with resultant "'In uptake by the tumour (Saha &
Farrer, 1975; Ando et al., 1982). The tissue distribution of
the two agents differed markedly: the former localised
primarily in the liver with lower uptake by other tissues; in
contrast, the latter rapily accumulated in the kidneys, other
tissues showing greater uptake and slower clearance. This is
further evidence that the two "'In preparations are handled
differently in vivo. (d) The presence of excess unlabelled DHE
did not prevent the tumour uptake of "'In DHE. Indeed
some enhancement of tumour uptake was observed, with
reduced uptake of "'In DHE into the liver (Figure 5).
The mechanism of the cold DHE effect is not clear. It
might be due to the saturation of binding sites in the liver
whose affinity for cold DHE is greater than for the "'In
labelled DHE, thus causing increased uptake of the latter by
the tumour. Perhaps this is a clue to structural modifications
that could be made to DHE to reduce liver binding and
enhance tumour uptake.
These findings suggest that "'In DHE may be useful as a
quantitative indicator of tumour DHE uptake. It would be
premature to use the term 'tracer', which implies a very close
correspondence between the biological properties of the
agents; this may not be the case for "'In DHE. The experi-
ment using cold DHE is excess showing uptake of "'In DHE
which was significantly increased over the tumour but
reduced over the liver, thus suggestive of interference by cold
DHE in the biological uptake of the radiolabelled porphyrin.
Therefore, the term 'tracer' in this case must be used with
caution.
Following administration of "'In chloride, measurements
of "'In over the tumour area by region of interest (ROI) in
vivo scanning differed from the results obtained by direct
counting of perfused and dissected tissues. Of the total "'In
21.3% was detected over the tumour area by gamma-camera
imaging, but only 5.8% g-I was measured in the dissected
tumour tissue (Table III). The remaining tracer must have
been retained in the oedematous tissue and exudate sur-
rounding the tumour, as shown by preliminary measurements
of tumour exudate in "'In chloride treated mice showing
three times the blood concentration of "'In (unpublished
results). In contrast, "'In DHE detected over the tumour
area by gamma-camera imaging corresponded well to the
direct counting of the dissected tumour tissue, suggesting the
possibility that gamma-camera imaging can be used to esti-
mate the tumour uptake of radiolabelled DHE. The compar-
ative cellular and extracellular tumour distribution of "'In
DHE and "'In given as the chloride was not addressed in
this study and clearly requires further investigation.
The much slower tissue turnover of "'In administered as
the chloride (Figure 2) is presumably due to its binding to
transferrin in the plasma, with long lived vascular and extra-
vascular components (Hosain et al., 1969; McIntyre et al.,
1974). In contrast, the rapid turnover of "'In DHE corres-
ponds to the fast blood clearance of 14C-DHE observed by
Bellnier et al. (1988) and is likely to be due to rapid passage
of the agent into the gut without an hour after administra-
tion. In support of this, we have demonstrated (unpublished)
marked passage of radioindium into rabbit gut within an
hour of "'In DHE i.v. injection.
Metallation of hematoporphyrin in the tetrapyrrole ring is
considered to have an inhibitory effect on tumour affinity for
the agent (Zanelli & Kaelin, 1981; Wang et al., 1981). We
speculate that the observed tumour uptake is due in part to
incomplete "'In labelling of DHE, which contains more than
80% dimers and oligomers, and that the unmetallated por-
phyrins present within the radiolabelled dimers or oligomers
may retain tumour affinity. In support of this hypothesis,
recent preliminary experiments (unpublished) have shown
that when "'In DHE was additionally labelled with stable
indium, tissue and tumour uptake of the radiolabelled agent
was much reduced.
Significantly elevated tissue:muscle ratios (P<0.005) for
"'In DHE in comparison to "'In chloride were found for
tumour, lung, spleen and liver, though not for skin (ear),
bone (marrow) or kidney (Table II). The relatively increased
uptake by the liver, spleen, lungs and tumour indicates the
existence of concentrative mechanisms. That the former three
organs are involved suggests uptake of radiolabelled DHE by
the reticuloendothelial system (Bugelski et al., 1981), but
another uptake mechanism by tumour may also be involved.
Kessel (1986) has described the binding of tumour-localising
porphyrins to high and low density lipoproteins (HDL and
LDL) which have been shown to transport HPD (Jori et al.,
1984; Reyftmann et al., 1984). Increased LDL receptors have
been associated with neoplastic cells (Norata et al., 1984; Gal
et al., 1981). A combination of altered vascular permeability,
poor lymphatic drainage and a lipoprotein receptor mechan-
ism could lead to increased tumour cell uptake.
The question obviously arises as to whether "'In DHE
might be useful as a tumour imaging agent. We do not have
enough information to answer this, except that its relatively
rapid clearance from the uninvolved tissues might improve
the resolution of those tumours which take up the agent. The
heavy uptake by liver and spleen would, however, be a
drawback. More studies with tumours of human origin in
addition to animals models are clearly necessary.
The main value of the present observations appears to lie
in the possibility ofestimating in vivo the degree ofporphyrin
uptake by tumours in phototherapy for cancer. Needless to
say, mice are not men, and human tumour biology differs
from that of transplanted murine tumours. In view of the
lack of past success using various radiolabelled porphyrins in
the limited patient studies that have so far been carried out.
caution is advisable in making any predictions as to how
these agents may behave in humans.
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